Unlocking Neurodegenerative Disease Insights: Large-Scale Single-Cell Analysis Initiative
A New Era in Understanding Alzheimer’s and Parkinson’s
A collaborative effort between Parse Biosciences and researchers at Mount Sinai’s Icahn School of Medicine is poised to generate a landmark single-cell dataset focused on the intricate mechanisms of selective splicing in neurodegenerative diseases like Alzheimer’s and Parkinson’s. This ambitious project aims to move beyond conventional genomic approaches and delve into the critical role of post-transcriptional processes in disease progress and progression.
The Challenge of Neurodegenerative Diseases & The Role of Splicing
Neurodegenerative diseases represent a growing global health crisis. according to the Alzheimer’s Association, over 6.7 million Americans are currently living with Alzheimer’s disease, and this number is projected to reach nearly 13 million by 2050. Parkinson’s Disease affects approximately one million Americans, with diagnoses expected to rise as the population ages (Parkinson’s Foundation). while genetic factors contribute to risk, the underlying molecular pathways driving these diseases are complex and often poorly understood.
Recent research highlights the importance of RNA splicing – the process by which genetic details is decoded to create proteins – as a key regulator of cellular function. Selective splicing, a variation of this process, allows cells to create multiple protein variants from a single gene. Disruptions in selective splicing have been increasingly linked to neurodegenerative conditions,suggesting a potential therapeutic target. However, studying these events at scale has been a important hurdle.
Pioneering a High-Throughput Single-Cell Approach
This new initiative addresses this challenge by leveraging the power of single-cell RNA sequencing. the study will analyze transcriptome maps of over 10 million cells derived from more than 1,000 peripheral blood mononuclear cell (PBMC) samples donated by patients diagnosed with Alzheimer’s or Parkinson’s disease.
This large-scale approach is crucial as neurodegenerative diseases are not uniform; they manifest differently in individuals and even within different cell types. Analyzing individual cells allows researchers to identify subtle variations in splicing patterns that would be masked in bulk tissue analysis – akin to listening for individual instruments in an orchestra rather than just the overall sound.
Parse Biosciences & the Power of GigaLab
The Mount Sinai team will utilize Parse Biosciences’ Evercode™ chemistry and the capabilities of Parse GigaLab, a state-of-the-art facility designed for generating large-scale single-cell datasets.GigaLab’s high-throughput capacity and focus on data quality will accelerate the research process, enabling faster insights into disease mechanisms.
“GigaLab’s speed and scale really help speed up the research process and allow us to gain insights like never before,” highlights the collaborative benefit of this partnership.
Implications for Future Research & Treatment
The data generated from this study will serve as a foundational resource for the scientific community, fostering breakthroughs in understanding, detecting, and ultimately treating neurodegenerative diseases. By identifying key splicing events and their impact on disease pathology, researchers can:
Develop more accurate diagnostic biomarkers: Identifying unique splicing signatures associated with early disease stages.
Identify novel therapeutic targets: Focusing on pathways that regulate aberrant splicing.* Personalize treatment strategies: Tailoring therapies based on an individual’s specific splicing profile.
Parse Biosciences, founded on technology originating from the University of Washington, has rapidly become a leader in single-cell sequencing, serving over 2,500 customers globally and securing over $100 million in funding. Their suite of technologies, including Evercode™ Whole Transcriptome, Evercode™ TCR, and Trailmaker™, are designed to empower researchers to unlock the complexities of cellular biology and accelerate discoveries in human health.